Authors


Kevin Hughes, MD

Latest:

Kevin Hughes, MD, on Breast Cancer Treatment Moving Forward

The breast cancer expert spoke about decreasing the amount of treatment to receive the same impact for patients with breast cancer.


Hope Rugo, MD

Latest:

Hope S. Rugo, MD, Talks Aromatase Inhibitors Plus Ribociclib in HR+/HER2– Advanced Breast Cancer

Hope S. Rugo, MD, FASCO, gave an overview of ribociclib plus aromatase inhibitor use vs abemaciclib plus aromatase inhibitors for patients with hormone receptor-positive, HER2-negative advanced breast cancer.


Patricia Jakel, RN, MN, AOCN

Latest:

Patricia Jakel, RN, MN, AOCN, On Treating Patients with CDK 4/6 Inhibitors

The clinical nurse specialist was also diagnosed with stage III invasive lobular breast cancer and was treated with CDK 4/6 inhibitors, giving her the unique opportunity to speak to both the patient and clinical perspective.


Ashray Maniar, MD

Latest:

The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer

This review article discusses the concepts of a tumor microenvironment and a gut microbiome and their effects on responses to checkpoint inhibitors (CPIs). It also reviews recent research investigating these 3 topics, and how it can be applied to using CPIs in prostate cancer.


Amy E. Moran, PhD

Latest:

The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer

This review article discusses the concepts of a tumor microenvironment and a gut microbiome and their effects on responses to checkpoint inhibitors (CPIs). It also reviews recent research investigating these 3 topics, and how it can be applied to using CPIs in prostate cancer.





Sherrie Bhoori, MD

Latest:

Hepatocellular Carcinoma Recurrence After Liver Transplantation

The case of a 64-year-old white woman with hepatitis C virus infection-related well-compensated cirrhosis with hepatocellular carcinoma recuurence.


Tommaso Cascella, MD

Latest:

How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma

A thought-provoking installment of Clinical Quandaries is presented by Alejandro Gabutti, MD; and Tommaso Cascella, MD, of a 36-year-old patient with hepatitis C virus-related cirrhosis and a subsequent diagnosis of hepatocellular carcinoma.


Marco Bongini, MD

Latest:

Hepatocellular Carcinoma Recurrence After Liver Transplantation

The case of a 64-year-old white woman with hepatitis C virus infection-related well-compensated cirrhosis with hepatocellular carcinoma recuurence.


John Allen, MD

Latest:

Recurrent Small Cell Carcinoma of the Lung With Cutaneous Metastasis in Breast

Experts present a case of recurrent small cell lung cancer presenting with a cutaneous metastatic nodule in the right breast.


Eduardo Gonzalez-Ochoa, MD

Latest:

69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent

Experts discuss the case of a 69-year-old man with a history of metastatic prostate cancer previously treated with androgen deprivation therapy with leuprolide. 


Haydee Verduzco-Aguirre, MD

Latest:

69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent

Experts discuss the case of a 69-year-old man with a history of metastatic prostate cancer previously treated with androgen deprivation therapy with leuprolide. 



Madison Grinnell

Latest:

HPV and the Immune System in Head and Neck Cancers: Therapeutic Considerations

A review of the role of immune therapy in HPV-associated head and neck squamous cell carcinoma, along with the evidence and perspective behind differing therapeutic considerations.


Howard S. Hochster, MD

Latest:

Chemotherapy Drug Shortages: It’s Soluble

Howard S. Hochster, MD, reviews the potential solutions for the current chemotherapy drug shortages, and how this can be avoided in the future.


Brielle Benyon

Latest:

MAIC Study Finds Similar Results With Linvoseltamab/Teclistamab in R/R Multiple Myeloma

Similar outcomes were noted when linvoseltamab and teclistamab were analyzed as treatments for patients with relapsed/refractory multiple myeloma.


Judd W. Moul, MD, FACS

Latest:

Defining PSA Nadir After Definitive Therapy in Prostate Cancer 

Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer. 


Andrew Chang, MD

Latest:

Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute’s Initial Experience

Experts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.


Brenda Jimenez-Franco, MD

Latest:

Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab

Experts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events


Andrew A. Davis, MD

Latest:

Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and Oncology

Conflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.


Beth Fand Incollingo

Latest:

Sotorasib Demonstrates Promising Antitumor Activity in Advanced NSCLC

Sotorasib showed promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation.


Ryan McDonald

Latest:

FDA OKs Zanubrutinib to Treat Leukemia Subtypes

Patients with chronic lymphocytic leukemia and small lymphocytic leukemia can now receive treatment with zanubrutinib following its approval by the FDA.


Conor Killmurray

Latest:

Mirvetuximab Yields HRQOL Improvement in FRα-Positive Ovarian Cancer

Patient reported outcomes from the phase 3 MIRASOL trial showed improvement when mirvetuximab was used vs standard of care in folate receptor-alpha positive ovarian cancer resistant ovarian cancer.


Stephen Schuster, MD

Latest:

Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 Pandemic

Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.


Jessica Skarzynski

Latest:

Greater Sleep Disturbance Associated With External Factors in Patients With GI Cancers

In patients with gastrointestinal cancers, factors such as younger age and comorbidities, among others, were significantly associated with a greater likelihood of sleep disturbance.


Jason Harris

Latest:

Circulating KIM-1 May Predict Benefit With Atezolizumab in RCC

KIM-1 was the most significantly enriched circulating protein in recurrence vs baseline serum samples among patients in the IMmotion010 trial.


Eric Jonasch, MD

Latest:

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.


Amir Goldkorn, MD

Latest:

Amir Goldkorn, MD Talks Next Steps for SWOG 1216 Trial

The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.